India, June 2 -- Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC). The study met its primary OS endpoint.
DeLLphi-304 study was designed to evaluate the efficacy and safety of Imdelltra for the treatment of patients living with SCLC who progressed on or after a single line of platinum-based chemotherapy. Data from the study showed a median OS of 13.6 months with Imdelltra compared to 8.3 months with local SOC chemotherapy in SCLC patients.
The results will be presented a...